Burkitt lymphoma · 2 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cytarabine and Etoposide (CYVE) Variant #06 | — | R 4 351 | — | — | ~9.2 mo | ~2 | ~R 8 701 PFS proxy · indirect | — |
Cytarabine and Methotrexate (CYM) Variant #03 | — | R 649 | 21d | — | — | ~6 | ~R 3 893 indirect | — |
2 of 2 regimens shown